Abstract: The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.
Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
Abstract: Antimicrobial compounds from Epicoccum purpurascens (syn. E. negrum) for use against plant and fungi pathogens. An orange yellow metabolite was isolated, the structure elucidated as a small group of compounds Epipyrone A-C and fungicidal activity demonstrated against plant pathogens, for example Botrytis cinerea and Lecanicillium muscarium. Agricultural and pharmaceutical compositions are provided, and use thereof in treating microbial infections in an animal or plant are also provided.
Type:
Grant
Filed:
August 24, 2011
Date of Patent:
November 18, 2014
Assignee:
Biotelliga Holdings Limited
Inventors:
Roel van Ginkel, Andrew Ian Selwood, Alistair Lawrence Wilkins, Stephen Ford, Cody Calder
Abstract: Disclosed is a daidzein derivative as represented by formula (I), or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O—N,N-diethyl-aminoacetyl daidzein hydrochloride, prepared by the daidzein derivative of the present invention, has better solubility and effect for treating cardiovascular diseases.
Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
Type:
Application
Filed:
May 13, 2014
Publication date:
November 6, 2014
Inventors:
Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin
Abstract: Compositions of matter including (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine are disclosed herein. Further disclosed are methods of preparation of such compounds and the use of such compounds as anticancer agents.
Type:
Application
Filed:
July 21, 2014
Publication date:
November 6, 2014
Inventors:
Khalid A. El Sayed, Paul W. Sylvester, Fathy A. Behery
Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
Type:
Application
Filed:
March 18, 2014
Publication date:
October 30, 2014
Applicant:
MASSACHUSETTS EYE AND EAR INFIRMARY
Inventors:
Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
Abstract: A composition includes an extract of seeds of Bixa orellana for the photoprotection of the retinal pigment epithelium in mammals. The use of such a composition for the treatment of macular degeneration related to age (AMD) in mammals is also described.
Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
Abstract: The present invention provides protein (or peptide)-polysaccharide (or oligosaccharide) conjugates (PPC) as nanocapsular vehicles for nanoencapsulation of biologically active compounds, particularly nutraceuticals. The PPCs efficiently protect both hydrophobic (i.e., water insoluble) and hydrophilic (i.e., water soluble) nutraceuticals, to provide a composition which, when added to a beverage, disperses so as to provide a clear or transparent solution. In some embodiments, the PPCs are Maillard reaction based PPCs. Advantageously, the conjugates of the present invention protect the nutraceuticals from degradation, both during shelf life and upon gastric digestion.
Type:
Application
Filed:
May 4, 2014
Publication date:
October 30, 2014
Applicant:
Technion Research and Development Foundation LTD.
Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
Abstract: The invention relates to extracts, in particular non-nutrient phytochemicals, form sugar cane or sugar beet waste products, such as molasses, sugar mud and bagasse, which have Glycemic Index (GI) lowering properties and their use as sweeteners and in foods containing sugar.
Abstract: The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The compound used in the present invention can improve quality of life in the human subjects with gastrointestinal disorders, are similarly effective in treating male and female subjects, and also effective in a human subject aged even 65 years and older.
Abstract: This invention provides a method of preventing and/or treating thymus degeneration comprising administering an effective amount of dihydromyricetin to a subject in need thereof, in which the degeneration is induced by dexamethasone. In one embodiment, the thymus degeneration is induced during the course of treatment of inflammation by dexamethasone.
Abstract: The invention provides compositions and methods for the prevention, amelioration, and/or treatment of diabetes complications, including ocular diseases associated with increased glucose transport and/or oxidative stress.
Abstract: A method of delaying digestion by an animal or a human of carbohydrates in food, comprising administering an effective amount of one or more flavonoids to the animal or human in conjunction with the food, wherein the flavonoids are selected from luteolin, apigenin, tricin and their pharmaceutically acceptable analogs and derivatives.
Type:
Grant
Filed:
January 27, 2012
Date of Patent:
October 21, 2014
Assignee:
BASF SE
Inventors:
Timothy Ralston Lang, Michael Gerard O'Shea
Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
Type:
Application
Filed:
October 26, 2012
Publication date:
October 16, 2014
Inventors:
Alexander Keith Stewart, Artem Plekhov, Robert Greenhouse
Abstract: Suggested is an antioxidant composition, comprising (a) caffeic acid, (b) sinapinic acid and, optionally, (c) polyphenols, with the proviso that components (a) and (b) are present in a weight ratio of about 85:15 to about 98:2.
Type:
Application
Filed:
April 9, 2014
Publication date:
October 16, 2014
Inventors:
Harry Erfurt, René Schuld, Melanie Stürtz, Christian Wintermeyer, Hans-Jürgen Niemeyer
Abstract: Water-soluble fluorinated analogs of natural curcumin, and particularly difluoro Knoevenagel condensates and Schiff bases, along with their corresponding copper (H) complexes have improved bioavailablity over curcumin. The fluorine-substituted analogs of curcumin are useful as chemopreventive and/or therapeutic agents against cancers and/or against the development of drug-resistant cancer. A preferred compound is (IE,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene{4(3,4 difluorobenzaldehyde)}-3,5-dione.
Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).
Abstract: Gene-Eden-VIR is a natural product that decreases the severity, duration, and frequency of symptoms during a viral infection, including infections with the Human Papillomavirus (HPV), Epstein Barr Virus (EBV), Herpes Simplex Virus (HSV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV).
Abstract: Non-therapeutic cosmetic or dermatological use of at least one of a compound selected from the group consisting of: gibberellic acids, naringenins, N-acetylaspartic acids, ?-aescin, arachadonic acid, quercetin, vitexin and docosahexaenoic acid (ethyl ester). Suitably, the use is in the treatment of, and/or prevention of, at least one sign of skin ageing or at least one sign of a skin damage condition associated with ageing, wherein the sign of skin ageing or skin damage is present on skin of the face, body or the scalp of a subject.
Type:
Application
Filed:
June 19, 2014
Publication date:
October 9, 2014
Inventors:
Johanna Maria GILLBRO, Alain Robert Pierre MAVON, Lucie DURACHER, Anke KLACK, Kevin CATTLEY
Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
Type:
Grant
Filed:
August 3, 2012
Date of Patent:
October 7, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Wilhelm Amberg, Udo Lange, Frauke Pohlki
Abstract: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.
Type:
Grant
Filed:
May 18, 2007
Date of Patent:
October 7, 2014
Assignee:
Janssen Pharmaceutica NV
Inventors:
Virginia L. Smith-Swintosky, David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Type:
Application
Filed:
June 17, 2014
Publication date:
October 2, 2014
Inventors:
William Forbes, Enoch Bortey, Steven King, Pravin Chaturvedi
Abstract: The invention relates to a skin anti-ageing composition. In particular a skin anti-ageing composition comprising myricetin or glycoside thereof, and at least one LXR alpha agonist. By skin ageing is meant the appearance or manifestation of any one or more of wrinkles or sagging, poor skin barrier such as dryness, scalp itch, or uneven skin tone such as age spots.
Type:
Application
Filed:
November 27, 2012
Publication date:
October 2, 2014
Applicant:
CONOPCO, INC. D/B/A UNILEVER
Inventors:
Gail Jenkins, Silvina Beatriz Lotito, Jennifer Elizabeth Pople, Linda Jane Wainwright
Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Abstract: The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer.
Type:
Application
Filed:
September 7, 2012
Publication date:
October 2, 2014
Applicant:
Deutsches Krebsforschungszentrum
Inventors:
Michael Platten, Christiane Opitz, Wolfgang Wick, Ulricke Litzenburger
Abstract: The present invention provides compositions comprising optimized ratios of Red clover phytoestrogens as determined by a proprietary physiologically based pharmacokinetic and pharmacodynamic model. The compositions are useful for modulating bone remodeling, and prevention and treatment of osteoporosis.
Type:
Application
Filed:
April 2, 2014
Publication date:
October 2, 2014
Inventors:
Yun Kau TAM, Yi-Chan James LIN, Brian Duff SLOLEY, Chih-Yuan TSENG
Abstract: This invention relates to the use of a composition comprising opioid/Toll-like receptor 4 (TLR4) antagonists and dextro enantiomers thereof for the treatment of pain, where the opioid antagonists treat pain by blocking TLR4. More preferably, the dextro opioid/TLR4 antagonist enantiomer treats pain by blocking TLR4 while not affecting the opioid receptors and therefore avoiding adverse effects associated with blocking the opioid receptors. Examples of opioid antagonist and their dextro enantiomers include naltrexone, naloxone and nalmefene, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
Abstract: Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression of the dominant negative form of RbAp48 is controlled by tetracycline-controlled transcriptional activation. Also provided are methods for evaluating in the transgenic mouse the potential therapeutic effect of an agent for slowing, inhibiting or preventing age-related memory decline in a mammalian subject.
Type:
Application
Filed:
August 2, 2012
Publication date:
October 2, 2014
Applicant:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
Scott A. Small, Ilias Pavlopoulos, Eric R. Kandel
Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
Type:
Grant
Filed:
July 27, 2011
Date of Patent:
September 30, 2014
Assignees:
President and Fellows of Harvard College, The General Hospital Corporation
Inventors:
David A. Sinclair, Maria Alexander-Bridges
Abstract: Isoflavone fatty acid ester derivatives of formula (I) or (II), the preparation method thereof and the pharmaceutical compositions containing such compounds are disclosed. The uses of such compounds in preparation of medicaments for preventing or treating hyperlipidemia, obesity or type II diabetes are also disclosed.
Type:
Grant
Filed:
March 1, 2010
Date of Patent:
September 30, 2014
Assignees:
China Pharmaceutical University, Nanjing Medical University Affiliated Brain Hospital
Inventors:
Hua Xiang, Wei Zhao, Hong Xiao, Yao Yao, Renling Ma, Lei Qian, Xiaobo Li, Qidong You, Qingjiang Liao
Abstract: The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.
Type:
Grant
Filed:
February 26, 2010
Date of Patent:
September 30, 2014
Assignee:
Catabasis Pharmaceuticals, Inc.
Inventors:
Chi B. Vu, Jean E. Bemis, Michael R. Jirousek, Jill C. Milne, Jesse J. Smith
Abstract: This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1), wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition said units of flavan-3-ol being bonded each other in any one of three patterns as follows; (i) a bond between carbon at the position 4 and carbon at the position 8, (ii) a bond between carbon at the position 4 and carbon at the position 6, (iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon, at the position 2 and oxygen at the position 7.
Abstract: The present invention provides a medicinal and/or a food usage of eupatilin for treating, improving, and/or preventing at least one condition selected from bone disease, menopausal disorder, cardiovascular disease, neurodegenerative disease, or obesity. Advantages of the present invention includes little or no possibility of side effects such as cancer, and effective treatment, improvement, and/or prevention of the at least one condition selected from bone disease, menopausal disorder, cardiovascular disease, neurodegenerative disease, and obesity.
Type:
Application
Filed:
September 27, 2012
Publication date:
September 25, 2014
Inventors:
Jung-Hye Choi, Kyung-Tae Lee, Ji-Hyun Kim, Nam-In Baek
Abstract: The present invention relates to a composition and a kit for the protection, treatment and repair of cartilage in humans and animal joints. The composition or kit contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. Preferably, the composition or kit contains avocado:soybean unsaponifiables (ASU) and green tea.
Type:
Application
Filed:
June 4, 2014
Publication date:
September 25, 2014
Inventors:
Todd R. Henderson, Louis Lippiello, Charles Filburn, David Griffin
Abstract: Disclosed are nanoparticle-based medicine/nutrient delivery system that are coated or incorporated with oxidized phospholipids as targeting ligands. Such delivery systems can specifically target macrophages, which are determinant cells in the aortic wall for atherosclerotic lesion development, to significantly increase bioavailability and specificity for the prevention, diagnosis and treatment of atherosclerosis.
Abstract: The present invention relates to methods of isolating flavonoids from Euphorbia cuneata, and a pharmaceutical composition comprising the flavonoids or the extracts or both of them for a use as anti-ulcer agent. The present invention further relates to a method of providing an anti-ulcer treatment to an animal in need thereof comprising administering to the animal a compound selected from 4?-methoxy-luteolin-7-O-rhamnoglucoside and aromadendrin. A method of providing an anti-ulcer treatment to an animal in need thereof comprising administering to the animal a compound selected from 4?-methoxy-luteolin-7-O-rhamnoglucoside and aromadendrin, in which the compound(s) are isolated from Euphorbia cuneata.
Type:
Application
Filed:
June 5, 2014
Publication date:
September 25, 2014
Inventors:
Amani S. AWAAD, Reham Moustafa EL-MELIGY
Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.
Type:
Application
Filed:
March 21, 2014
Publication date:
September 25, 2014
Applicant:
EcoBiotics Ltd
Inventors:
Paul Warren Reddell, Victoria Anne Gordon
Abstract: The present invention provides for a formulation manufactured by a process comprising: admixing at least one elastomer with a first dispersant to form a gel; admixing a second dispersant with the gel; and admixing at least one active, such as ascorbic acid, with the gel to form a delivery system with an active in the formulation retains its stability, functionality and aesthetics.
Abstract: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.
Abstract: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, and compositions thereof, which also has fragrance properties, may be used commercially for its insect repellent properties.
Abstract: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
Type:
Application
Filed:
March 12, 2014
Publication date:
September 18, 2014
Inventors:
Hao Zhang, Peter T.W. Cheng, Sean Chen, Shiwei Tao, Shung C. Wu, Lidet A. Negash
Abstract: A method for repelling blood-sucking and biting insects, ticks and mites involving treating an object or area with a blood-sucking and biting insects, ticks and mites repelling effective amount of camphor lactams, verbenone lactams, dolicholactams, dolicholactone, and their precursors, and mixtures thereof, and optionally a carrier.
Type:
Application
Filed:
March 14, 2013
Publication date:
September 18, 2014
Inventors:
Kamlesh R. Chauhan, Bheema R. Paraselli
Abstract: The present invention relates to a method and composition for treating safely (in a non-toxic way) disease or disorder exhibiting excessive cellular proliferation comprising administering to a patient needing such treatment, a composition comprising curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides, Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN).
Type:
Application
Filed:
March 5, 2014
Publication date:
September 18, 2014
Inventors:
Loic Pierre Deleyrolle, Brent Allan Reynolds
Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.